Prostate Intraductal Carcinoma clinical trials at UC Irvine

1 research study open to eligible people

Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
open to eligible males ages 18 years and up
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body …
Irvine, California and other locations

Our lead scientists for Prostate Intraductal Carcinoma research studies include David S. Hong.

Last updated: March 4, 2025

Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study